| Literature DB >> 34205106 |
Mateusz Lucki1, Ewa Chlebuś2, Agnieszka Wareńczak2, Przemysław Lisiński2.
Abstract
Background andEntities:
Keywords: CVD; ICF; secondary prevention; stroke
Mesh:
Year: 2021 PMID: 34205106 PMCID: PMC8199949 DOI: 10.3390/ijerph18116021
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Study design. CVD—cardiovascular disease; ICF—International Classification of Functioning, Disability and Health.
Characteristics of the study groups.
| Parameter | Variable | IS | ICH |
|
|---|---|---|---|---|
| Gender | Female | 28 (50.9%) | 20 (42.6%) | 0.399 a |
| Male | 27 (49.1%) | 27 (57.4%) | ||
| Age | Mean ± SD (years) | 69.3 ± 12.5 | 61.3 ± 12.6 | 0.002 b |
| Median (years) | 71.6 | 63.0 | ||
| Min–Max (years) | 43.0–93.0 | 27.0–81.0 | ||
| Treatment of stroke | Conservative | 46 (83.6%) | 36 (76.6%) | 0.375 a |
| Interventional | 9 (16.4%) | 11 (23.4%) | ||
| Conservative | Fatal incident CVD | 26 (86.7%) | 12 (100.0%) | 0.184 a |
| Recurrent CVD incident | 10 (83.3%) | 4 (57.1%) | 0.211 a | |
| No recurrent CVD incident | 10 (76.9%) | 20 (71.4%) | 0.712 a | |
| Interventional | Fatal incident CVD | 4 (13.3%) | 0 (0.0%) | 0.184 a |
| Recurrent CVD incident | 2 (16.7%) | 3 (42.9%) | 0.211 a | |
| No recurrent CVD incident | 3 (23.1%) | 8 (28.6%) | 0.712 a | |
| Time from first stroke to recurrent CVD incident | Mean ± SD (months) | 36.6 ± 24.9 | 36.6 ± 24.5 | 0.963 c |
| Median (months) | 36.0 | 36.0 | ||
| Min–Max (months) | 4.0–84.0 | 12.0–108.0 | ||
| Recurrent CVD incident: | 42 (76.4%) | 19 (40.4%) | <0.001 a | |
| IS | 34 (61.8%) | 19 (40.4%) | 0.031 a | |
| Myocardial infarction | 8 (14.5%) | 0 (0.0%) | <0.019 a | |
| Fatal incident | 30 (54.5%) | 12 (25.5%) | 0.003 a | |
| No recurrent CVD incident | 13 (23.6%) | 28 (59.6%) | <0.001 a |
CVD—cardiovascular disease; n: size of sample; IS—ischemic stroke; ICH—haemorrhagic stroke; SD—standard deviation; a chi-squared test; b Student’s t-test for independent variables; c Mann–Whitney test.
Analysis of the recurrence of CVD incidents, according to age and gender.
| Recurrent CVD Incident | YES | NO | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Fatal CVD Incidents | Non Fatal CVD Incidents | ||||||||
| Patients Groups | IS | ICH |
| IS | ICH |
| IS | ICH |
|
| <65 years | 8 (38.1%) | 5 (17.9%) | 0.206 a | 6 (28.6%) | 6 (21.4%) | 0.730 a | 7 (33.3%) | 17 (60.7%) | 0.102 a |
| ≥65 years | 22 (64.7%) | 7 (36.8%) | 0.099 a | 6 (17.7%) | 1 (5.3%) | 0.440 a | 6 (17.7%) | 11 (57.9%) | 0.016 a |
| Female | 34 (46.4%) | 5 (25.0%) | 0.267 a | 7 (25.0%) | 3 (15.0%) | 0.608 a | 8 (28.6%) | 12 (60.0%) | 0.061 a |
| Male | 17 (63.0%) | 7 (26.0%) | 0.030 a | 5 (18.5%) | 4 (14.8%) | 0.836 a | 5 (18.5%) | 16 (59.3%) | 0.015 a |
CVD—cardiovascular disease; F—female, M—male; IS—ischemic stroke; ICH—haemorrhagic stroke; a chi-squared test.
Analysis of the incidence of risk factors for CVD in secondary prevention, according to the clinical type of the previous stroke.
| ICF Category | Patients Groups | IS | ICH |
| IS | ICH |
| IS |
| ICH |
| ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recurrent CVD Incident | YES | YES | NO | NO | YES | NO | YES | NO | |||||
| b 152 Emontional functions—Depression | 10 (23.8%) | 6 (31.6%) | 0.521 | 2 (15.4%) | 7 (25.0%) | 0.490 | 10 (23.8%) | 2 (15.4%) | 0.522 | 6 (31.6%) | 7 (25.0%) | 0.620 | |
| b 134 Sleep functions Insomia | 10 (23.8%) | 7 (36.8%) | 0.294 | 2 (15.4%) | 11 (39.3%) | 0.126 | 10 (23.8%) | 2 (15.4%) | 0.522 | 7 (36.8%) | 11 (39.3%) | 0.863 | |
| b 4100 Heart rate | HR > 80/min, | 20 (48.8%) | 7 (36.8%) | 0.383 | 5 (38.5%) | 11 (39.3%) | 0.961 | 20 (48.8%) | 5 (38.5%) | 0.515 | 7 (36.8%) | 11 (39.3%) | 0.863 |
| b 4101 Heart rhythm | Atrial fibrillation, | 23 (54.8%) | 3 (15.8%) | 0.004 | 4 (30.8%) | 2 (7.1%) | 0.046 | 23 (54.8%) | 4 (30.8%) | 0.130 | 3 (15.8%) | 2 (7.1%) | 0.342 |
| b 4150 Functions of arteries | Stenosis 50–69%, | 12 (28.6%) | 6 (31.6%) | 0.812 | 3 (23.1%) | 2 (7.1%) | 0.145 | 12 (28.6%) | 3 (23.1%) | 0.697 | 6 (31.6%) | 2 (7.1%) | 0.028 |
| Stenosis > 70%, | 14 (33.3%) | 2 (10.5%) | 0.061 | 1 (7.7%) | 0 (0.0%) | 0.137 | 14 (33.3%) | 1 (7.7%) | 0.070 | 2 (10.5%) | 0 (0.0%) | 0.080 | |
| b 4200 Increased blood pressure | >140/90 mmHg, | 40 (95.2%) | 18 (94.7%) | 0.937 | 10 (76.9%) | 23 (82.1%) | 0.696 | 40 (95.2%) | 10 (76.9%) | 0.045 | 18 (94.7%) | 23 (82.1%) | 0.205 |
| b 4302 Metabolite-carrying functions of the blood | eGFR(mL/min/1.73 m2) <15, | 6 (14.3%) | 6 (31.6%) | 0.116 | 0 (0.0%) | 0 (0.0%) | 1.0 | 6 (14.3%) | 0 (0.0%) | 0.149 | 6 (31.6%) | 0 (0.0%) | 0.001 |
| Bilirubin >2x ULN, ALT/AST/ALP > 3x ULN, | 4 (9.5%) | 1 (5.3%) | 0.580 | 1 (7.7%) | 4 (14.3%) | 0.548 | 4 (9.5%) | 1 (7.7%) | 0.844 | 1 (5.3%) | 4 (14.3%) | 0.327 | |
| b 4303 Clotting functions. | VKA, | 8, (19.0%) | 3 (15.8%) | 0.763 | 3 (23.1%) | 2 (7.1%) | 0.145 | 8 (19..0%) | 3 (23.1%) | 0.747 | 3 (15.8%) | 2 (7.1%) | 0.342 |
| NOAC, | 7 (16.7%) | 1 (5.3%) | 0.222 | 2 (15.4%) | 1 (3.6%) | 0.178 | 7 (16.7%) | 2 (15.4%) | 0.912 | 1 (5.3%) | 1 (3.6%) | 0.778 | |
| b 5401 Carbohydrate metabolism | HbA1 > 7%, | 20 (47.6%) | 3 (15.8%) | 0.018 | 3 (23.1%) | 4 (14.3%) | 0.486 | 20 (47.6%) | 3 (23.1%) | 0.118 | 3 (15.8%) | 4 (14.3%) | 0.887 |
| b 7302 Lipid metabolism | LDL 55–70 mg/dL, | 3 (7.1%) | 13 (68.4%) | <0.001 | 3 (23.1%) | 18 (64.3%) | 0.014 | 3 (7.1%) | 3 (23.1%) | 0.106 | 13 (68.4%) | 18 (64.3%) | 0.771 |
| LDL 71–115 mg/dL, | 17 (40.5%) | 5 (26.3%) | 0.285 | 3 (23.1%) | 2 (7.1%) | 0.145 | 17 (40.5%) | 3 (23.1%) | 0.255 | 5 (26.3%) | 2 (7.1%) | 0.069 | |
| LDL > 116 mg/dL, | 22 (52.4%) | 0 (0.0%) | <0.001 | 3 (23.1%) | 0 (0.0%) | 0.008 | 22 (52.4%) | 3 (23.1%) | 0.064 | 0 (0.0%) | 0 (0.0%) | 1.0 | |
| e1100 Food | Alcohol consumption > 10 g (>1 unit), | 01 (2.4%) | 1 (5.3%) | 1.0 | 0 (0.0%) | 2 (7.1%) | 0.325 | 1 (2.4%) | 0 (0.0%) | 0.573 | 1 (5.3%) | 2 (7.1%) | 0.804 |
| e 1101 Drugs | NSAIDs, | 34 (81.0%) | 3 (15.8%) | <0.001 | 12 (92.3%) | 4 (14.3%) | <0.001 | 34 (81.0%) | 12 (92.3%) | 0.335 | 3 (15.8%) | 4 (14.3%) | 0.887 |
| e1109 Products or substances for personal consumption, other specified | Smoking, | 16 (38.1%) | 6 (31.6%) | 0.671 | 3 (23.1%) | 5 (17.9%) | 0.696 | 16 (38.1%) | 3 (23.1%) | 0.320 | 6 (31.6%) | 5 (17.9%) | 0.277 |
ALT—alanine aminotransferase; AST—aspartate aminotransferase; ALP—alkaline phosphatase; BP—blood pressure; CVD—cardiovascular disease; eGFR—estimated glomerular filtration rate; ICH—intracerebral haemorrhage; ICF—International Classification of Functioning, Disability and Health; IS—ischemic stroke; HbA1c—glycated haemoglobin 1c; HR—heart rate; LDL-C—low-density lipoprotein cholesterol; n—size of the sample; NOAC—nonvitamin K antagonist oral anticoagulants; NSAIDs—nonsteroidal anti-inflammatory drugs; ULN—upper limit of normal; VKA—vitamin K antagonist.
Profile of CVD risk factors as per categories of the ICF classification.
ALT—alanine aminotransferase; AST—aspartate aminotransferase; ALP—alkaline phosphatase; BP—blood pressure; CVD—cardiovascular disease; eGFR—estimated glomerular filtration rate; ICH—intracerebral haemorrhage; ICF—International Classification of Functioning, Disability and Health; IS—ischemic stroke; HbA1c—glycated haemoglobin 1c; HR—heart rate; LDL-C—low-density lipoprotein cholesterol; n—size of the sample; NOAC—nonvitamin K antagonist oral anticoagulants; NSAIDs—nonsteroidal anti-inflammatory drugs; ULN—upper limit of normal; VKA—vitamin K antagonist; Red color—extreme problems; Orange color—significant problems; Yellow color—moderate problems; Light green color—minor problems; Dark green color—no problems.
Comparison of the total incidence of CVD risk factors.
| Risk Factors for Recurrent CVD Incident | ||||||
|---|---|---|---|---|---|---|
| Patients Groups | IS |
| ICH |
| ||
| Recurrent CVD Incident | YES | NO | YES | NO | ||
| Mean ± SD | 7.3 ± 2.0 * | 5.6 ± 3.0 | 0.031 a | 5.8 ± 1.6 | 4.3 ± 1.6 * | 0.002 b |
| Median | 7.0 | 4.0 | 6.0 | 4.0 | ||
| Min–Max | 4.0–12.0 | 2.0–11.0 | 3.0–8.0 | 1.0–7.0 | ||
CVD—cardiovascular disease; IS—ischemic stroke; ICH—haemorrhagic stroke; SD—standard deviation; a Mann–Whitney test; b Student’s t-test for independent variables; *—Wilcoxon test.
Figure 2Distribution of the total of CVD risk factors. CVD—cardiovascular disease; ICF—International Classification of Functioning, Disability and Health; IS—ischemic stroke.